

Total laparoscopic transabdominal-transdiaphragmatic approach for treating Siewert II tumors

Wei Pang

Sixth Medical Center of PLA General Hospital

Gang Liu

Sixth Medical Center of PLA General Hospital

Yan Zhang

Sixth Medical Center of PLA General Hospital

Yun Huang

Sixth Medical Center of PLA General Hospital

Xinpu Yuan

Sixth Medical Center of PLA General Hospital

Chaojun Zhang

Sixth Medical Center of PLA General Hospital

Zhanwei Zhao (✉ zzq194910@163.com)

UBS Pla de na Tesa <https://orcid.org/0000-0002-0485-8229>

Research

Keywords: Adenocarcinoma of the esophagogastric junction (AEG), Siewert II, Laparoscopic total gastrectomy

Posted Date: February 10th, 2020

DOI: <https://doi.org/10.21203/rs.2.23002/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Although the morbidity of gastric cancer has decreased, the incidence of adenocarcinoma of the esophagogastric junction (AEG) is increasing. Furthermore, no consensus exists on which surgical approach should be applied for Siewert type II AEG. The purpose of our study was to evaluate the technical safety and feasibility of a new surgical approach.

Methods: Sixty patients with Siewert type II AEG underwent laparoscopic total gastrectomy with the total laparoscopic transabdominal-transdiaphragmatic (TLTT) approach, which needs an incision in the diaphragm.

Results: The median operative time, reconstruction time and estimated blood loss were 214.8 ± 41.60 mins, 29.40 ± 7.09 mins and 209.00 ± 110.27 ml, respectively. All of the patients had negative surgical margins.

Conclusion: There were no intraoperative complications or conversions to open surgery. Our surgical procedure provides a unique option for the safe application of laparoscopic lower mediastinal lymph node dissection and gastrointestinal reconstruction.

Trial Registration: Chinese Clinical Trial Registry, ChiCTR1800014336. Registered 31 December 2017- Prospectively registered, <http://www.chictr.org.cn/edit.aspx?pid=23111&htm=4>.

Background

Adenocarcinoma of the esophagogastric junction (AEG) refers to adenocarcinoma that straddles the area of the esophagogastric junction (EGJ), including the distal esophagus and the proximal stomach, and is considered to have a high morbidity and low survival[1]. The incidence of gastric cancer (GC) worldwide has declined in the last 30 years. However, the incidence of AEG has increased rapidly in both Asian and Western countries[2]. Data from the Surveillance, Epidemiology, and End Results cancer registry program in the United States showed an approximate 2.5-fold increase in the incidence of AEG in the past 35 years. Moreover, the overall five-year survival rates during this period were less than 12%[3]. As an East Asian region with a high incidence of GC, the statistical results of a Japanese cancer monitoring research group revealed that the proportion of AEG among all gastric adenocarcinomas increased from 2.3% in early 1960 to 10% in 2000, while the proportion of Siewert type II disease rose from 28.5–57.3%, but that of type I remained at approximately 1%[4]. In China, statistics from the single center of the West China Hospital of Sichuan University indicated that the proportion of AEG among all gastric adenocarcinomas has increased from 22.3–35.7% in the past 20 years[5].

In 1996, Siewert et al classified AEG into three subtypes according to the location of the tumor's epicenter. Type I tumors of the distal esophagus have a center 1–5 cm above the junction. Type II, true carcinoma of the cardia, has a center between 1 cm proximal and 2 cm distal from the EGJ. Type III, subcardial gastric carcinoma, has a center 2–5 cm distal from the junction. Based on a retrospective review of 1602

consecutive resected patients[6], esophagectomy should be used for the treatment of type I tumors, while extended total gastrectomy should be adopted for the treatment of type II and type III tumors. In recent years, Western and Asian authors have reached a general agreement about the optimal surgical method for Siewert type I and III tumors, which is to apply total gastrectomy with distal esophagectomy with lower mediastinal lymphadenectomy and esophagectomy with a two-field Ivor Lewis operation via an exclusive abdominal approach.

However, no standard surgical method has been chosen for Siewert type II tumors to date. Subtotal esophagectomy with proximal gastrectomy through the transhiatal or transthoracic method or total gastrectomy with partial esophagectomy through a transhiatal approach is usually chosen. Takiguchi et al[7] was the first in the world to report 6 cases of total laparoscopic transabdominal-transdiaphragmatic (TLTT) surgery and concluded that the diaphragmatic approach can provide a better surgical view for lymph node dissection and anastomotic reconstruction. However, due to the small sample size, the safety and effectiveness of this procedure still need to be further studied.

Thus, we conducted a single-center prospective study to further evaluate the safety and feasibility of the TLTT method for the treatment of Siewert II tumors. This study has been registered on the Chinese Clinical Trial Register (ChiCTR1800014336).

Materials And Methods

Patients and specimens

This study was conducted at the Sixth Medical Center of PLA General Hospital. From February 2018 to January 2019, 60 consecutive patients suffering from AEG type II were chosen for this study. Endoscopy and computed tomography (CT) were included in the preoperative diagnostic evaluation. All the tumors covered in this study were histologically proven as AEG and defined as Siewert type II AEG. Tumor stage was classified based on the 8th edition of the TNM staging system of the International Union Against Cancer (UICC) for GC. Furthermore, the lymph node stations were numbered based on the definitions of the Japanese Gastric Cancer Association[8].

More than 2,000 laparoscopic gastrectomy procedures have been performed by the same surgical group each year. This group obtained professional training for laparoscopic surgery beforehand. The possible risks and complications were known to the patients. All patients provided written informed consent before the operation, and this study was approved by the ethics committee of our hospital (Number of ethics approval: 2017011). The clinicopathological features of the patients are summarized in Table 1.

Surgical Procedure

Typically, under general anesthesia, the patients were placed in a reverse Trendelenburg position with their legs apart. The umbilicus was chosen for the camera port, which can permit a flexible laparoscope

to be introduced with a 10-mm trocar. Altogether, four other trocars were inserted into the upper abdomen, which is demonstrated in Fig. 1. During this process, the assistant stood on the right side of the patient, while the surgeon usually stood on the left side of the patient. The video laparoscope operator filmed from a distal position and stood between the patients' legs.

The abdominal cavity was explored and revealed no metastases in the greater omentum, peritoneum, free fluid or liver. During the process of mobilizing the stomach, the left gastroepiploic artery (No. 4sb), the short gastric artery (No. 4sa) and other lymph nodes were removed. Subsequently, the suprapancreatic lymph nodes were excised. This led to the removal of the lymph nodes around the left gastric artery (No. 7), common hepatic artery (No. 8a, No. 8p), celiac artery (No. 9), and proximal splenic artery (No. 11p). The lower perigastric lymph nodes (No. 5, No. 6) were removed during routine D2 lymphadenectomy.

The left gastric artery was classified and ligatured. Extra dissection and splenectomy of the No. 10 lymph nodes were not regularly performed. Afterwards, the abdominal esophagus was exposed circumferentially by the phrenoesophageal ligament (Fig. 2). Both sides of the crus were cut open with an ultrasonic device to release the distal and cardia esophagus. During the operation, the right pericardial (No. 1), left pericardial (No. 2), and lesser curvature (No. 3) lymph nodes were thoroughly removed. The laparoscopic dissection of the mediastinal lymph nodes was obstructed by the diaphragm around the lower esophagus. A 10 cm anterior incision was made routinely in the diaphragmatic crus via a coagulating device, and an abundant working space was created to enhance the view of the mediastinal space (Fig. 3). After dissection of the muscle fibers of the esophageal hiatus cross-section, the thoracic aorta was exposed. The esophageal artery was classified and confirmed during dissection of the posterior layer of the esophagus. The dissection of the left side of the distal esophagus and anterior esophagus was conducted down to the level of the tracheal bifurcation. The surgeon incised the left parietal pleura close to the pericardium. Afterwards, the surgeon opened the left thoracic cavity to the mediastinal space. The incision was extended to the left pulmonary aortic arch and hilum. Therefore, the mediastinum and the left thoracic cavity were connected, leading to a large surgical field. The right side of the mediastinum tissues was used for the dissection and preservation of the parietal pleura surface of the right lung. In this manner, the lower thoracic esophageal (No. 110), supradiaphragmatic (No. 111), and posterior mediastinal (No. 112) nodes were dissected. The transection plane of the esophagus was determined through intraoperative endoscopy. A 5-mm articulating endoscopic linear stapler was used to transect the esophagus 5 cm above the proximal margin. Intraoperative frozen pathology studies were routinely conducted.

At the stump of the esophagus, a 25-mm circular stapler anvil head was placed, with hand-sewn purse-string sutures or a suture made with a needle through an esophagotomy. A circular stapler was used to perform the intracorporeal end-to-side esophagojejunostomy. A 60-mm endoscopic linear stapler was used at the distal stump of the jejunum. A linear stapler could also be used. The anastomosis could be made in the functional end-to-end anastomosis manner or the side-to-side fashion, which is known as the "overlap method", in which two prongs of a linear stapler were inserted into the jejunum via a small hole made 5 cm from the edge. On the esophageal stump, another hole was made. Meanwhile, side-to-side

anastomosis was performed. Subsequently, a hand-sewn technique was used to close the common entry hole either with interrupted sutures or a continuous suture. Two abdominal drainage tubes were placed in either side of the esophageal anastomosis. Repairing the hiatus of the diaphragm through the suture is important to avoiding hiatal hernia (Fig. 4).

Statistical analysis

Statistical analyses were performed by using SPSS 21.0. Categorical data were compared by Fisher's exact test or χ^2 test. Consecutive data are presented as the mean \pm standard deviation (SD). T-tests or rank-sum tests were used to compare the means of two groups. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. Multivariable correlations between covariates with survival were investigated by using Cox proportional hazard models. $P < 0.05$ was considered statistically significant.

Results

To date, these 60 patients have already successfully undergone TLTT resection for AEG type II. There were no patients of AEG type III. The tumor size was 31.62 ± 9.11 cm. Nine patients underwent preoperative chemotherapy. Table 1 presents the clinical features of the participants in this study.

Table 1
Characteristics of the patients in this study (N = 60).

Sex	51 (85%)
Male	9 (15%)
Female	
Age (year)	66.10 \pm 11.14
BMI (kg/m ²)	22.98 \pm 2.69
Tumor size (mm)	31.62 \pm 9.11
Tumor classification	60 (100%)
Siewert type II AEG	0 (0%)
Siewert type III AEG	
Neoadjuvant chemotherapy	9 (15%)
+	51 (85%)
-	
BMI: Body mass index. AEG: Adenocarcinoma of the esophagogastric junction.	

All of these patients had negative surgical margins. The circular stapler was used in 27 patients, of whom 24 patients received hand-sewn purse-string sutures, and 3 patients received a suture with a needle through an esophagotomy. Additionally, functional end-to-end anastomosis was performed with a linear

stapler in 24 patients. The overlap method was used in 9 patients. No conversions to open surgery were needed. The median operative time and reconstruction time were 214.8 ± 41.60 min and 29.40 ± 7.09 min, respectively. There were no reductions in oxygen saturation while the thoracic cavity was open in any patients with a pneumoperitoneum. Table 2 demonstrates the pathological and surgical findings.

Table 2
Surgical and pathological results (N = 60).

Type of surgery	60 (100%)
Total gastrectomy	
Operative time (min)	214.8 ± 41.60
Reconstruction time (min)	29.40 ± 7.09
Reconstruction type	24 (40%)
Using circular staplers	3 (5%)
Hand-sewn purse-string sutures	24 (40%)
Others	9 (15%)
Using linear staplers	
Functional end-to-end anastomosis	
Overlap method	
Length of esophageal exposure (cm)	9.44 ± 1.79
Number of lymph nodes dissected	37.26 ± 11.11
Blood loss (ml)	209.00 ± 110.27
Tumor depth (pathological)	9 (15%)
T1	15 (25%)
T2	15 (25%)
T3	21 (35%)
T4	
Nodal status (pathological)	24 (40%)
N0	9 (15%)
N1	6 (10%)
N2	21 (35%)
N3	
Histological type	48 (80%)
Differentiated	12 (20%)
Undifferentiated	

Four patients had postoperative complications, including anastomotic leakage, anastomotic twist, pulmonary infection and incisional infection. There were no deaths at postoperative time. The postoperative complications are shown in Table 3.

Table 3

Postoperative complications (N = 60)

Postoperative complications	4
Anastomotic leakage	1
Anastomotic twist	1
Pulmonary infection	1
Incisional infection	1

Discussion

Surgical alternatives for Siewert II AEG are proximal gastrectomy or total gastrectomy with partial esophagectomy through subtotal esophagectomy, the transhiatal method through a hiatal/transabdominal method or a transthoracic method. The procedure is usually chosen according to the size and location of tumors[11]. However, the approach has not been standardized so far.

Theoretically, a safer upper surgical margin and better lower mediastinal lymph node dissection can be obtained through the transthoracic method. The elevated risk of perioperative pulmonary complications induced by thoracotomy can be prevented with the abdominal method. Hulscher et al[9] implemented a randomized controlled trial to compare the abdominal/transhiatal approach and the IL approach for the treatment of adenocarcinoma of the gastric cardia and distal esophagus. There were no notable differences between these two groups in terms of the quality-adjusted survival, disease-free survival or median overall survival. Wei et al[10] performed a meta-analysis to compare transhiatal surgery and transthoracic surgery for AEG. No difference was shown in the general survival of patients with Siewert type II AEG between the two groups. However, transhiatal surgery would result in reduced pulmonary complications and a shortened hospital stay. As shown by the Japan Clinical Oncology Group (JCOG9502), the transhiatal method was superior to left thoracotomy in the treatment of AEG type II and III tumors with esophageal invasion depths of less than 3 cm[11].

The possibility of an improper proximal margin over the esophagus is one challenge in achieving R0 resection with tumors. A negative proximal margin of a minimum of 5 cm was advocated for by classic teaching. Barbour et al[12] proposed that at least 3.8 cm isolated proximal surgical margins and 5 cm margins in situ should be included in the radical resection for T2 + stage AEG. Later, Mine et al[13] demonstrated that a 2-cm proximal surgical margin in situ was sufficient for AEG. To date, no standard proximal surgical margin exists for Siewert type II AEG. Hosoda et al[14] suggested that the lymph nodes of stations 1, 2, 3, and 7 can be dissected in Siewert type II and III AEG due to their high indexes of estimated benefit from lymph node dissection (IEBLDs). According to the report from Kurokawa et al[15], metastasis is associated with Siewert type II AEG ≥ 2 cm. Patients suffering from esophageal invasion deeper than 3 cm should undergo dissection of the inferior mediastinal lymph nodes. Lee et al[16] and Peng et al[17] proposed that removing the mediastinal lymph nodes would help decrease the symptoms of advanced cancers. To date, no standard adequate lymphadenectomy approach exists.

In our study, the left diaphragm was opened to create a relatively large surgical field. High anastomosis in patients with esophageal invasion remains a technical challenge. The insertion of an anvil head in the

esophagus is a major obstacle. It is difficult to apply functional end-to-end anastomosis with linear staplers in the mediastinum. The side-to-side (“overlap”) approach can be successfully used for tumors involving the distal esophagus. Thus, the overlap approach was the main anastomosis method that we chose[18–20].

In our study, the diaphragmatic hiatus was generally split to obtain better exposure for lymph node reconstruction and dissection if the tumor invaded the distal esophagus. When the reconstruction was conducted over the deeper mediastinum, a laparoscopic opening in the left diaphragm was helpful. A negative proximal margin of more than 5 cm was achieved in each patient. Thorough lymph node dissection was performed, including the thoracic esophageal nodes (No. 110), supradiaphragmatic nodes (No. 111) and posterior mediastinal nodes (No. 112). This preliminary study suggested that this operation mainly has the following advantages in comparison with the combined abdominal approach and traditional left thoracic approach (IL). First, surgeons could stay in fixed positions without changing the patient’s position during the operation, which obviously shortened the operation time and avoided turning the patient from a supine position. Second, the procedure was rather simple. Only a 5–10 cm incision was made laparoscopically on the diaphragm. Therefore, the surgical field could be expanded, which would be conducive to reducing the difficulty of anastomosis reconstruction and lymphatic dissection. Third, the dissection of suspicious lymph nodes and thorough resection of the surgical margin were achieved through this TLTT procedure. Metastasis can be prevented, and the prognosis can be improved. Fourth, the surgical method began at the abdomen and moved to the chest afterwards. The operation process for the chest is comparatively shorter than that for the abdomen. This can dramatically decrease interference to both the lungs and the heart. In the comparison with the transabdominal esophageal perforation method, this procedure has the following advantages: shorter operation time, simple anastomosis operation, larger operation space and better vision.

Although this surgical procedure was safe and feasible and the advances of this method were obvious, the limitations in our study should be recognized, including the single postoperative assessment and retrospective design. Prospective clinical trials should be used to evaluate the benefits of this new surgical technique.

Conclusions

The TLTT method for AEG type II can be applied safely and is technically feasible after surgeons obtain proper experience in performing laparoscopic proximal gastrectomy and laparoscopic total gastrectomy. However, this still remains a very advanced and complex laparoscopic procedure. The esophagojejunal anastomosis in the lower mediastinum is particularly demanding in terms of techniques. It is recommended that this operation should be performed by experienced laparoscopic surgeons.

Abbreviations

AEG: Adenocarcinoma of the esophagogastric junction; GC: Gastric cancer; EGJ: Esophagogastric junction; TLTT: Total laparoscopic transabdominal-transdiaphragmatic

Declarations

Ethics approval and consent to participate: All patients provided written informed consent before the operation, and this study was approved by the ethics committee of our hospital (Number of ethics approval: 2017011). This study has been registered on the Chinese Clinical Trial Register (ChiCTR1800014336).

Consent for publication: Not applicable

Availability of data and materials: The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by funding from the Innovation Funds of Navy General Hospital (CXPY201801) and the Funds of Bethune Charitable Foundation (HZB-20181119-71).

Authors' contributions WP and ZZ wrote the main manuscript and participated in the study design and the data analysis. GL and YZ analyzed and interpreted the patient data. YH and XY modified the article. CZ was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

References

1. Han WX, Chen ZM, Wei ZJ, Xu AM: **Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction.** *World J Surg Oncol* 2016, **14**:279.
2. Li Z, Dong J, Huang Q, Zhang W, Tao K: **Comparison of three digestive tract reconstruction methods for the treatment of Siewert II and III adenocarcinoma of esophagogastric junction: a prospective, randomized controlled study.** *World J Surg Oncol* 2019, **17**:209.
3. Buas MF, Vaughan TL: **Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease.** *Semin Radiat Oncol* 2013, **23**:3-9.
4. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, Shimoda T: **Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan.** *J Gastroenterol Hepatol* 2008, **23**:1662-1665.
5. Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, et al: **Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China.** *Ann Surg* 2016, **263**:88-95.

6. Feith M, Stein HJ, Siewert JR: **Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients.** *Surg Oncol Clin N Am* 2006, **15**:751-764.
7. Takiguchi S, Miyazaki Y, Shinno N, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Mori M, Doki Y: **Laparoscopic mediastinal dissection via an open left diaphragm approach for advanced Siewert type II adenocarcinoma.** *Surg Today* 2016, **46**:129-134.
8. Japanese GCA: **Japanese Classification of Gastric Carcinoma - 2nd English Edition -.** *Gastric Cancer* 1998, **1**:10-24.
9. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, Ten KF, van Dekken H, Obertop H, et al: **Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.** *N Engl J Med* 2002, **347**:1662-1669.
10. Wei MT, Zhang YC, Deng XB, Yang TH, He YZ, Wang ZQ: **Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.** *World J Gastroenterol* 2014, **20**:10183-10192.
11. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M: **Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.** *Lancet Oncol* 2006, **7**:644-651.
12. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: **Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.** *Ann Surg Oncol* 2007, **14**:306-316.
13. Mine S, Sano T, Hiki N, Yamada K, Kosuga T, Nunobe S, Yamaguchi T: **Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction.** *Br J Surg* 2013, **100**:1050-1054.
14. Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M: **Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.** *World J Gastroenterol* 2017, **23**:2723-2730.
15. Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, Wada N, Takiguchi S, Mine S, Hasegawa S, et al: **Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction.** *Surgery* 2015, **157**:551-555.
16. Lee IS, Ahn JY, Yook JH, Kim BS: **Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.** *World J Surg Oncol* 2017, **15**:28.
17. Peng J, Wang WP, Yuan Y, Hu Y, Wang Y, Chen LQ: **Optimal Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junction Adenocarcinoma.** *Ann Thorac Surg* 2015, **100**:263-269.
18. Bracale U, Marzano E, Nastro P, Barone M, Cuccurullo D, Cutini G, Corcione F, Pignata G: **Side-to-side esophagojejunostomy during totally laparoscopic total gastrectomy for malignant disease: a multicenter study.** *Surg Endosc* 2010, **24**:2475-2479.
19. Inaba K, Satoh S, Ishida Y, Taniguchi K, Isogaki J, Kanaya S, Uyama I: **Overlap method: novel intracorporeal esophagojejunostomy after laparoscopic total gastrectomy.** *J Am Coll Surg* 2010, **211**:e25-e29.

20. Zhang H, Wang W, Cheng Y, Song Y, Zhu K, Dang C: **Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.** *World J Surg Oncol* 2013, **11**:155.

Figures



Figure 1

The position of patient and the sites of trocars.




Figure 2

The abdominal esophagus was exposed circumferentially by the phrenoesophageal ligament.




Figure 3

An abundant working space was created to enhance the view of the mediastinal space.




Figure 4

Repairing the hiatus of the diaphragm through the suture.